跳至主要内容
临床试验/NCT00547560
NCT00547560已完成1 期

An Ascending Multiple Dose Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of GSI-953 Administered Orally To Healthy Elderly Subjects

Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
49
试验地点
1
主要终点
The pharmacokinetic and pharmacodynamic profile for the elderly subjects.

研究概览

简要总结

To assess the safety and tolerability of ascending, multiple, oral doses of GSI-953 in healthy elderly subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women, greater than or equal to 65 years of age.
  • Women of nonchildbearing potential (WONCP) may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for greater than or equal to 1 year (with FSH greater than or equal to 38 mIU/mL) and must have a negative pregnancy test result within 48 hours before administration of test article. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound.
  • Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight >50 kg.

排除标准

  • 未提供

研究组 & 干预措施

GSI+Placebo

Other

干预措施: GSI-953 (Drug)

结局指标

主要结局

The pharmacokinetic and pharmacodynamic profile for the elderly subjects.

时间窗: 6 months

次要结局

  • Pharmacokinetics (PK)(6 months)
  • Pharmacodynamics (PD)(6 months)

研究者

发起方
Wyeth is now a wholly owned subsidiary of Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验